Using renin levels to predict septic shock severity and outcomes
Renin Levels as Prognostic Indicators of Septic Shock Severity and Outcome: Prospective Cohort Study (SOS Trial)
This study is testing if measuring renin levels in the blood can help doctors predict how severe septic shock will be and how patients will do in the ICU.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Federal Research and Clinical Centre of Intensive Care Medicine and Rehabilitology Academic / other |
| Locations | 1 site (Moscow) |
| Trial ID | NCT06545838 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the role of plasma renin concentration as a prognostic indicator for the severity of septic shock and patient outcomes. It focuses on patients aged 18 and older who are hospitalized in the intensive care unit with a confirmed diagnosis of sepsis within the last 24 hours. By analyzing renin levels alongside established markers like procalcitonin and lactate, the study seeks to fill gaps in the current understanding of sepsis severity assessment. The findings could lead to improved clinical decision-making in managing septic shock.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are hospitalized in the ICU with a confirmed diagnosis of sepsis.
Not a fit: Patients who have undergone recent surgical interventions on the kidneys or adrenal glands may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the ability to predict outcomes in septic shock patients, potentially leading to better-targeted therapies.
How similar studies have performed: While the use of renin as a prognostic marker in septic shock is less explored, other studies have shown promise in using various biomarkers for similar purposes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Hospitalization in the intensive care unit * Confirmed diagnosis of Sepsis within 24 hours * Signed informed consent or a decision by the medical council to include the patient in the study Exclusion Criteria: * Any surgical intervention on the kidneys and/or adrenal glands performed within 28 days prior to the patient's inclusion in the study * Patients previously included in this study
Where this trial is running
Moscow
- Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology — Moscow, Russia (Recruiting)
Study contacts
- Principal investigator: Valery Likhvantsev, PhD — Federal Research and Clinical Centre of Intensive Care Medicine and Rehabilitology
- Study coordinator: Valery Likhvantsev, PhD
- Email: lik0704@gmail.com
- Phone: +79036235982
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.